Furthermore, the new International Ki67 in Breast Cancer Working Group recommendations have been established, providing specific and detailed guidelines for each step of Ki67 assessment with the levels of evidence for its technical validity and clinical utility as a biomarker [44]. This evidence concerns the gene MKI67 and breast carcinoma.